The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / EU Approves Remsima SC, a Biosimilar to Infliximab

EU Approves Remsima SC, a Biosimilar to Infliximab

January 2, 2020 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In late November 2019, the E.U. approved the use of CT-P13 SC (Remsima SC), a subcutaneous formulation biosimilar to infliximab, to treat adults with rheumatoid arthritis (RA) in combination with methotrexate and to treat adult patients for whom disease-modifying anti-rheumatic drugs (DMARDs) have proved inadequate. The treatment can also be used for patients with active, severe and progressive RA who have not been previously treated with methotrexate or other DMARDs.1

You Might Also Like
  • Switch to Biosimilar Infliximab for IBD Slashes Drug Costs
  • FDA Approves Amgen’s Infliximab Biosimilar Treatment
  • Mucosal Healing Seen with Infliximab Biosimilar CT-P13 in Ulcerative Colitis
Also By This Author
  • Efficacy Studied Following Accelerated Drug Approvals

Background
This approval was based on a clinical drug-switching study. At Week 30 of the study, adult RA patients were switched from receiving intravenous infliximab to receive CT-P13 SC. The clinical response of the patients who switched treatments was comparable to that of patients who remained on CT-P13 SC through Week 54. A safety evaluation was completed through Week 64.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

After this approval of CT-P13 SC, it’s expected that patients may be able to self-inject the medication at home. This approach has the potential to significantly reduce hospital and physician visits. Also, using subcutaneous infliximab at home has the potential to save patient and healthcare provider time, because intravenous infliximab preparation and administration in a healthcare setting would no longer be required.

Celltrion has applied for patent protection for CT-P13 SC in approximately 100 countries, including the U.S. and many countries in Europe and Asia.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

  1. Celltrion Healthcare Co. Ltd. News release: Celltrion Healthcare receives EU marketing authorisation for world’s first subcutaneous formulation of infliximab, Remsima SC for the treatment of people with rheumatoid arthritis. 2019 Nov 26.

Filed Under: Biologics & Biosimilars, Drug Updates

You Might Also Like:
  • Switch to Biosimilar Infliximab for IBD Slashes Drug Costs
  • FDA Approves Amgen’s Infliximab Biosimilar Treatment
  • Mucosal Healing Seen with Infliximab Biosimilar CT-P13 in Ulcerative Colitis
  • Infliximab Biosimilar Cross Reacts to Infliximab Antibodies; Plus Treat-to-Target Strategy Promising for Treating RA with bDMARDs

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.